|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM359823661 |
| 003 |
DE-627 |
| 005 |
20231226081711.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109700
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1199.xml
|
| 035 |
|
|
|a (DE-627)NLM359823661
|
| 035 |
|
|
|a (NLM)37482118
|
| 035 |
|
|
|a (PII)S1521-6616(23)00463-1
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Gokani, Bindi
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Behçet's patients' response to COVID-19 vaccination
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 02.10.2023
|
| 500 |
|
|
|a Date Revised 02.10.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Immune hyperstimulation by SARS-CoV2 results in multi-system involvement with consequent organ damage not dissimilar to Behçet's Disease (BD). Management of BD includes immunosuppressive medication, which led to concerns that; firstly, SARS-CoV-2 would stimulate BD activity, thrombin, clotting times, TPO antibodies, and the effectiveness and duration of the COVID-19 vaccines' response in this potentially vulnerable group. The main objectives of this study were: to assess BD patients' immune response to the COVID-19 vaccines based on age, gender, disease activity, BD phenotype, and immunomodulatory medication compared to healthy control participants by measuring anti-spike IgG levels. Further to evaluate the effect of the COVID-19 vaccines on T and B cells, immunoglobulins, thrombophilia, thyroid function and COVID-19 antibody production. Patients on immunosuppressive medication had a reduced immune response to COVID-19 vaccines. -Also, patients over 40 years and with the neurologic BD phenotype had lower responses. mRNA COVID-19 vaccines were more effective and had fewer side effects compared to conventional COVID-19 vaccines
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Anti-spike IgG
|
| 650 |
|
4 |
|a Behçet's disease response
|
| 650 |
|
4 |
|a COVID-19 vaccines
|
| 650 |
|
4 |
|a Immunosuppressive medication
|
| 650 |
|
4 |
|a Nucleocapsid IgG
|
| 650 |
|
4 |
|a SARS-CoV-2
|
| 650 |
|
7 |
|a COVID-19 Vaccines
|2 NLM
|
| 650 |
|
7 |
|a RNA, Viral
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Viral
|2 NLM
|
| 700 |
1 |
|
|a Sacoor, Sarah
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Leisegang, Georgia R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ogunkolade, William
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bibi, Azimoon
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Grigoriadou, Sofia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pade, Corinna
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gibbons, Joseph
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Senusi, Amal
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fortune, Farida
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 255(2023) vom: 15. Okt., Seite 109700
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:255
|g year:2023
|g day:15
|g month:10
|g pages:109700
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109700
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 255
|j 2023
|b 15
|c 10
|h 109700
|